[go: up one dir, main page]

PE20180609A1 - Composiciones farmaceuticas solidas para el tratamiento del vhc - Google Patents

Composiciones farmaceuticas solidas para el tratamiento del vhc

Info

Publication number
PE20180609A1
PE20180609A1 PE2018000084A PE2018000084A PE20180609A1 PE 20180609 A1 PE20180609 A1 PE 20180609A1 PE 2018000084 A PE2018000084 A PE 2018000084A PE 2018000084 A PE2018000084 A PE 2018000084A PE 20180609 A1 PE20180609 A1 PE 20180609A1
Authority
PE
Peru
Prior art keywords
compound
hcv
pharmaceutically acceptable
treatment
solid pharmaceutical
Prior art date
Application number
PE2018000084A
Other languages
English (en)
Inventor
Katharin Asmus
Yi Gao
Colleen Garrett
Harald Hach
Adivaraha Jayasankar
Samuel Kyeremateng
Ute Lander
Thomas Mueller
Marius Naris
Constanze Obermiller
Regina Reul
Katrin Schneider
Nancy Sever
Michael Siimon
Benedikt Steitz
Ping Tong
Ulrich Westedt
Donghua Zhu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/192,211 external-priority patent/US20160375087A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20180609A1 publication Critical patent/PE20180609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referido a una composicion farmaceutica solida que comprende: (1) 100 mg del compuesto 1, asi como un polimero hidrofilo farmaceuticamente aceptable y un tensioactivo farmaceuticamente aceptable, todos los cuales estan formulados en dispersion solida amorfa; y (2) 40 mg del compuesto 2, asi como un polimero hidrofilo farmaceuticamente aceptable y un tensioactivo farmaceuticamente aceptable, todos los cuales estan formulados en una dispersion solida amorfa. En donde, el compuesto 1 es un potente inhibidor de proteasa del virus de la Hepatitis C (VHC), y el compuesto 2 es un potente inhibidor de la proteina no estructural NS5 A. Por ende, esta composicion farmaceutica es util en el tratamiento de la hepatitis C.
PE2018000084A 2015-07-17 2016-07-18 Composiciones farmaceuticas solidas para el tratamiento del vhc PE20180609A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
US15/192,211 US20160375087A1 (en) 2015-06-26 2016-06-24 Solid Pharmaceutical Compositions for Treating HCV

Publications (1)

Publication Number Publication Date
PE20180609A1 true PE20180609A1 (es) 2018-04-09

Family

ID=57834557

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000084A PE20180609A1 (es) 2015-07-17 2016-07-18 Composiciones farmaceuticas solidas para el tratamiento del vhc

Country Status (22)

Country Link
EP (1) EP3324941A1 (es)
JP (2) JP7133466B2 (es)
KR (2) KR102824158B1 (es)
CN (1) CN108024964B (es)
AU (1) AU2016296709C1 (es)
BR (1) BR112018000982A2 (es)
CA (1) CA2992722C (es)
CL (1) CL2018000138A1 (es)
CO (1) CO2018000391A2 (es)
CR (1) CR20180088A (es)
DO (1) DOP2018000024A (es)
EA (1) EA201890334A1 (es)
EC (1) ECSP18008411A (es)
HK (1) HK1255203A1 (es)
IL (1) IL256945B2 (es)
MX (1) MX2018000746A (es)
PE (1) PE20180609A1 (es)
PH (1) PH12018500132A1 (es)
RU (1) RU2018105849A (es)
SG (1) SG10202002900YA (es)
WO (1) WO2017015211A1 (es)
ZA (1) ZA201801082B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
SG11202111196RA (en) * 2019-04-08 2021-11-29 Abbvie Inc Solid pharmaceutical compositions for treating hcv

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
LT2498758T (lt) 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
KR102163902B1 (ko) * 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
MX362616B (es) 2013-03-14 2019-01-28 Abbvie Inc Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
CR20180030A (es) 2015-06-26 2018-05-24 Abbvie Inc Composiciones farmacéuticas sólidas para el tratamiento del vhc.

Also Published As

Publication number Publication date
HK1255203A1 (zh) 2019-08-09
JP7133466B2 (ja) 2022-09-08
CA2992722C (en) 2023-10-17
AU2016296709C1 (en) 2022-02-24
KR102824158B1 (ko) 2025-06-25
CR20180088A (es) 2018-05-24
AU2016296709A1 (en) 2018-02-08
JP2018520185A (ja) 2018-07-26
CN108024964B (zh) 2022-05-03
KR20180025317A (ko) 2018-03-08
BR112018000982A2 (pt) 2018-09-11
EP3324941A1 (en) 2018-05-30
PH12018500132A1 (en) 2018-07-23
KR20240108528A (ko) 2024-07-09
RU2018105849A3 (es) 2019-12-13
CL2018000138A1 (es) 2018-07-13
IL256945B1 (en) 2023-06-01
NZ739127A (en) 2024-05-31
MX2018000746A (es) 2018-08-15
CN108024964A (zh) 2018-05-11
JP2022141719A (ja) 2022-09-29
IL256945A (en) 2018-03-29
NZ775565A (en) 2024-05-31
SG10202002900YA (en) 2020-05-28
WO2017015211A1 (en) 2017-01-26
JP7472199B2 (ja) 2024-04-22
AU2016296709B2 (en) 2021-11-11
CO2018000391A2 (es) 2018-06-12
RU2018105849A (ru) 2019-08-19
CA2992722A1 (en) 2017-01-26
IL256945B2 (en) 2023-10-01
ECSP18008411A (es) 2018-04-30
EA201890334A1 (ru) 2018-06-29
DOP2018000024A (es) 2018-04-15
ZA201801082B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
ECSP17064986A (es) Compuestos antivirales
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
CL2014000612A1 (es) Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CO6761348A2 (es) Compuestos antivirales
UY37997A (es) Agentes antivirales contra la hepatitis b
MX2021005850A (es) Heterociclos funcionalizados como agentes antivirales.
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
MX346264B (es) Compuestos antivirales.
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
CO2018009559A2 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
PE20180609A1 (es) Composiciones farmaceuticas solidas para el tratamiento del vhc
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
ECSP13012552A (es) Formas en estado sólido de un potente inhibidor del vch.
BR112017028185A2 (pt) composições farmacêuticas sólidas para tratar hcv
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv